| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Fungal[1]
Pyromeconic acid targets fungi through its antifungal activity. It is a potent inhibitor of endonuclease. The compound also inhibits tyrosinase, affecting the melanogenesis pathway. Its diverse targets include fungal components and enzymes involved in melanin production. It is classified as an antifungal agent with endonuclease inhibitory activity. |
|---|---|
| ln Vitro |
In glass plates covered with silica gel, a concentration of 15 μg/80 mm2 of pyreconic acid is required to demonstrate inhibition of fungal growth[1]. The nature of pyrenoconic acid is siderophilic and water soluble[1].
In vitro, Pyromeconic acid shows antifungal activity with a minimum concentration of 15 μg/80 mm2 required to inhibit fungal growth on silica gel-coated glass plates. It is a potent inhibitor of endonuclease. The compound also inhibits tyrosinase, disrupting melanin production. Its water-soluble and siderophilic properties contribute to its bioactivity. |
| ln Vivo |
In vivo, Pyromeconic acid has been studied for its antifungal activity in animal models of fungal infection. Its water-soluble properties make it suitable for various formulations. However, detailed in vivo efficacy, pharmacokinetic, and toxicological data are limited. Further studies are needed to fully characterize its in vivo potential and therapeutic applications.
|
| Enzyme Assay |
For non-cellular assays, Pyromeconic acid is evaluated for its antifungal activity using agar diffusion or broth microdilution methods. Endonuclease inhibition is assessed using biochemical assays with purified endonuclease enzymes. Tyrosinase inhibition is evaluated using enzymatic assays with purified tyrosinase and appropriate substrates. The compound's siderophilic properties are assessed using iron-binding assays.
|
| Cell Assay |
In vitro cell culture experiments are performed using fungal pathogens and melanin-producing cells. Fungi are treated with Pyromeconic acid at various concentrations. Endpoints include fungal growth inhibition (zone of inhibition, MIC), endonuclease activity, and melanin production. Cytotoxicity to mammalian cells is assessed using standard cell viability assays to evaluate selectivity. The compound's water-soluble properties facilitate its use in cell culture assays.
|
| Animal Protocol |
In vivo animal studies are conducted in mouse models of fungal infection or other relevant models. Pyromeconic acid is administered orally, intravenously, or topically. Efficacy is assessed by measuring fungal burden in target organs, survival rates, and clinical signs of infection. Pharmacokinetic parameters such as bioavailability, half-life, and tissue distribution are determined to guide dosing regimens. The compound's water-soluble properties facilitate formulation for in vivo administration.
|
| ADME/Pharmacokinetics |
Pyromeconic acid has a molecular formula of C5H4O3 and a molecular weight of 112.08 g/mol. It is a small molecule with water-soluble properties. The compound is typically dissolved in water or DMSO for in vitro studies and formulated in appropriate vehicles for in vivo administration. Pharmacokinetic properties are not fully characterized, but the compound's water solubility suggests good bioavailability.
|
| Toxicity/Toxicokinetics |
Pyromeconic acid shows antifungal activity with a minimum inhibitory concentration of 15 μg/80 mm2. It is a potent endonuclease inhibitor and also inhibits tyrosinase. The compound is water-soluble and has siderophilic properties. Standard laboratory safety precautions should be followed during handling. The compound is for research use only.
|
| References | |
| Additional Infomation |
Reports have indicated that Erigeron brevicorum, Ageratum indicum, and Erigeron annuus contain 3-hydroxy-4H-pyran-4-one, and relevant data are available for reference.
Pyromeconic acid (3-hydroxy-4H-pyran-4-one) is an antifungal substance and a potent endonuclease inhibitor. It inhibits fungal growth at 15 μg/80 mm2 and inhibits tyrosinase. The compound has water-soluble and siderophilic properties. It is used in research on antifungal agents and enzyme inhibition. It is for research use only. |
| Molecular Formula |
C5H4O3
|
|---|---|
| Molecular Weight |
112.08
|
| Exact Mass |
112.016
|
| CAS # |
496-63-9
|
| PubChem CID |
68129
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
298.7±40.0 °C at 760 mmHg
|
| Melting Point |
117-118ºC
|
| Flash Point |
139.9±20.8 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.593
|
| LogP |
-0.57
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
167
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VEYIMQVTPXPUHA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H4O3/c6-4-1-2-8-3-5(4)7/h1-3,7H
|
| Chemical Name |
3-hydroxypyran-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.9222 mL | 44.6110 mL | 89.2220 mL | |
| 5 mM | 1.7844 mL | 8.9222 mL | 17.8444 mL | |
| 10 mM | 0.8922 mL | 4.4611 mL | 8.9222 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
